Prostate Cancer

The ENZAMET trial represents a landmark achievement in prostate cancer research, demonstrating significant survival benefits for men with metastatic hormone-sensitive prostate cancer (mHSPC). This international phase III study, led by ANZUP in collaboration with the NHMRC Clinical Trials Centre, established enzalutamide as an important addition to first-line androgen deprivation therapy (ADT), showing improved outcomes compared […]

Tempus AI has launched the ArteraAI Prostate Test (mHSPC), the first externally developed digital pathology algorithm integrated into the Tempus clinical ecosystem. The AI-powered, CLIA-certified assay combines histopathology, clinical data, and genomic insights to improve risk stratification and guide personalized therapy intensity decisions for patients with metastatic hormone-sensitive prostate cancer.

The expanded DEAR-EXT study found that darolutamide delivered superior real-world outcomes compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer. Across 1,375 patients, darolutamide was associated with lower discontinuation rates, delayed metastatic progression, and improved metastasis-free survival, supporting its use as a preferred first-line ARI for high-risk nmCRPC.

The Oncologic Drugs Advisory Committee (ODAC) voted 7 to 1, with one abstention, that the regimen demonstrated a favorable benefit-risk profile for AstraZeneca’s TRUQAP (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). The recommendation, based on results from the phase 3 CAPItello-281 trial, highlights […]

The combination of talazoparib (Talzenna) and enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) in patients with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC) in the Phase III TALAPRO-3 trial. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression or death […]

The FDA has granted full approval to rucaparib, an oral PARP inhibitor, for adults with BRCA1/2-mutated metastatic castration-resistant prostate cancer following progression on androgen receptor-directed therapy, supported by Phase 3 TRITON3 data demonstrating a significant improvement in radiographic progression-free survival compared with physician’s choice therapy.

High-risk biochemically recurrent (hrBCR) prostate cancer represents a clinically challenging disease state, characterized by rising prostate-specific antigen (PSA) levels despite prior definitive local therapy and the absence of radiographic metastases on conventional imaging. Historically, androgen deprivation therapy (ADT) alone has been the standard approach, though outcomes have remained suboptimal. Results from the phase III EMBARK […]

FDA approves Akeega (niraparib + abiraterone acetate with prednisone) for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant improvements in radiographic progression-free survival and delayed symptomatic progression, with a safety profile consistent with the individual therapies.